FILSPARI secures full European approval: A major breakthrough for IgA nephropathy patients

Pallavi Madhiraju- April 29, 2025 0

Find out how FILSPARI’s full EU approval marks a major step for IgA nephropathy treatment and strengthens CSL Vifor and Travere Therapeutics’ rare disease focus. Read More

American Regent’s HEART-FID trial for INJECTAFER fails to meet primary endpoint

Pallavi Madhiraju- August 27, 2023 0

American Regent, Inc., a subsidiary of Daiichi Sankyo Group, has announced disappointing results from its phase 3 HEART-FID trial of INJECTAFER (ferric carboxymaltose injection) for ... Read More